We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

The First Discovery of a Single Digit Nanomolar Small Molecule Blocker of a Protein-protein Interaction Target

Video   Jul 03, 2015

 



About the Speaker
Dr. Nils Hansen is the CEO and founder of Vipergen ApS. He is the principal inventor of the enabling YoctoReactor® and Binder Trap Enrichment® drug discovery technology platforms. He previously worked for Praecis Pharmaceuticals Inc., (Waltham, MA, USA) and Symphogen A/S, (Copenhagen, Denmark). Dr. Hansen earned his Ph.D. in immunology from the University of Copenhagen, Denmark in 2000 and his M.Sc. in Chemistry and Biotechnology from the University of Aarhus, Denmark in 1996.Abstract
Effective small molecule PPI blocker discovery using high fidelity DNA-encoded libraries and a low-noise homogeneous screening assay. The screen employs a unique principle of trapping small molecule binders together with the protein target in miniscule droplets.

 
 
 
Advertisement
 

Recommended Videos

How Fast Can a Vaccine Be Made?

Video

When a new pathogen emerges, our bodies and healthcare systems are left vulnerable. And when this pathogen causes the outbreak of a pandemic, there’s an urgent need for a vaccine to create widespread immunity with minimal loss of life. So how quickly can we develop vaccines when we need them most?

WATCH NOW

TSE Explores Drug Discovery – Testing a Drug Compound: Clinical Trials

Video

In this episode we speak with Dr Stephen Wright, Consultant in Medicines Development from Limber Strategic, who talks to us about the clinical development of a drug, including how clinical trials are designed and the role of regulatory authorities in the process.

WATCH NOW

TSE Explores Drug Discovery – Identifying and Optimizing a Promising Drug

Video

In this episode we speak with Professor Paul Brennan from the University of Oxford about lead optimization, what to consider when designing a new drug, and much more.

WATCH NOW

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE